

UCLA

UCLA Previously Published Works

Title

Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease.

Permalink

<https://escholarship.org/uc/item/50q4p3hh>

Journal

PloS one, 10(4)

ISSN

1932-6203

Authors

Gagnon, Philippe
Casaburi, Richard
Saey, Didier
et al.

Publication Date

2015

DOI

10.1371/journal.pone.0123626

Peer reviewed

RESEARCH ARTICLE

Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease

Philippe Gagnon¹, Richard Casaburi², Didier Saey¹, Janos Porszasz², Steeve Provencher¹, Julie Milot¹, Jean Bourbeau³, Denis E. O'Donnell⁴, François Maltais^{1*}

1 Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada, **2** Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America, **3** Respiratory Epidemiology and Clinical Research Unit, Montréal Chest Institute, McGill University, Montréal, Québec, Canada, **4** Queen's University and Kingston General Hospital, Kingston, Ontario, Canada

* Francois.Maltais@fmed.ulaval.ca



OPEN ACCESS

Citation: Gagnon P, Casaburi R, Saey D, Porszasz J, Provencher S, Milot J, et al. (2015) Cluster Analysis in Patients with GOLD 1 Chronic Obstructive Pulmonary Disease. PLoS ONE 10(4): e0123626. doi:10.1371/journal.pone.0123626

Academic Editor: Konstantinos Kostikas, University of Athens Medical School, GREECE

Received: September 4, 2014

Accepted: February 20, 2015

Published: April 23, 2015

Copyright: © 2015 Gagnon et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This work was supported by a Canadian Institutes of Health Research (CIHR; <http://cihr-irsc.gc.ca/e/193.html>) grant MOP-84091 and by an unrestricted research grant from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Pfizer Inc. who were given the opportunity to check the data used in the manuscript for factual accuracy only and were not involved in the study design, data collection, analysis or interpretation. Writing, editorial support and formatting assistance was provided by Jane M. Gilbert, BSc CMPP, of Envision Scientific Solutions,

Abstract

Background

We hypothesized that heterogeneity exists within the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 spirometric category and that different subgroups could be identified within this GOLD category.

Methods

Pre-randomization study participants from two clinical trials were symptomatic/asymptomatic GOLD 1 chronic obstructive pulmonary disease (COPD) patients and healthy controls. A hierarchical cluster analysis used pre-randomization demographics, symptom scores, lung function, peak exercise response and daily physical activity levels to derive population subgroups.

Results

Considerable heterogeneity existed for clinical variables among patients with GOLD 1 COPD. All parameters, except forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC), had considerable overlap between GOLD 1 COPD and controls. Three-clusters were identified: cluster I (18 [15%] COPD patients; 105 [85%] controls); cluster II (45 [80%] COPD patients; 11 [20%] controls); and cluster III (22 [92%] COPD patients; 2 [8%] controls). Apart from reduced diffusion capacity and lower baseline dyspnea index versus controls, cluster I COPD patients had otherwise preserved lung volumes, exercise capacity and physical activity levels. Cluster II COPD patients had a higher smoking history and greater hyperinflation versus cluster I COPD patients. Cluster III COPD patients had reduced physical activity versus controls and clusters I and II COPD patients, and lower FEV₁/FVC versus clusters I and II COPD patients.

which was contracted and compensated by BIPI and Pfizer Inc for these services.

Competing Interests: The authors of this manuscript have the following competing interests: PG declares that he has no competing interests. RC is a consultant for Boehringer Ingelheim, Forest and Novartis. He has served on advisory boards for Boehringer Ingelheim and Forest, and has received payment for lectures including service on speakers' bureaus from AstraZeneca, Boehringer Ingelheim, Forest, Novartis and Pfizer. He has received payment for development of educational presentations from Boehringer Ingelheim. His institution has received grants from Boehringer Ingelheim, Forest, GlaxoSmithKline and Novartis. DS declares that he has no competing interests. JP reports grants from Boehringer Ingelheim, Inc., personal fees from Boehringer Ingelheim, Inc., non-financial support from Boehringer Ingelheim, Inc., personal fees from Actelion, during the conduct of the study. In addition, he has a patent US 7,628,732 and a patent US 7,927,251 issued. SP is a clinician scientist of the Fonds de la Recherche en Santé du Québec. He has served on advisory boards for Actelion, Eli Lilly, GlaxoSmithKline and Pfizer and has received payment for lectures from Actelion and Eli Lilly. His institution has received grants from Actelion, Bayer and GlaxoSmithKline. JM is a clinician scientist of the Fonds de la Recherche en Santé du Québec and declares that she has no competing interests. JB is a recipient of a CIHR/Rx&D Collaborative Research Program Operating Grants (# 93326) for The Canadian Cohort of Obstructive Lung Disease (CanCOLD). He received research funding via the Research Institute of the McGill University Health Centre, from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer and Theratechnologies; and has served on speakers, consultation panels and/or advisory boards for the above listed pharmaceutical companies. DEO has served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Pfizer and Roche. He has received payment for lectures including service on speakers' bureaus from Boehringer Ingelheim, GlaxoSmithKline and Pfizer. His institution has received grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed and Pfizer. FM holds a GSK/CIHR Research Chair on COPD at Université Laval. He is a consultant for Boehringer Ingelheim. He has served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline and Pfizer and has received payment for lectures including service on speakers bureaus from Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Pfizer. His institution has received grants from Boehringer Ingelheim and GlaxoSmithKline. This does not alter

Conclusions

The results emphasize heterogeneity within GOLD 1 COPD, supporting an individualized therapeutic approach to patients.

Trial registration

www.clinicaltrials.gov. [NCT01360788](https://clinicaltrials.gov/ct2/show/study/NCT01360788) and [NCT01072396](https://clinicaltrials.gov/ct2/show/study/NCT01072396).

Introduction

According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [1] spirometric classification, mild airflow obstruction is defined by a post-bronchodilator forced expired volume in 1 second (FEV₁) to forced vital capacity (FVC) ratio at a fixed cut-off of <0.70 and an FEV₁ ≥80% predicted [2]. Although this grading severity system has proved to be of value in the assessment of chronic obstructive pulmonary disease (COPD), it is a simplistic approach, poorly representing the complexity of COPD [3].

According to the Burden of Obstructive Lung Disease (BOLD) study [4], which used the 2006 GOLD consensus report [5], patients with mild COPD represent nearly 45% of patients with COPD, the remainder being GOLD stage 2 to 4. Paradoxically, there is limited information on patients with mild COPD even though they represent a large portion of patients with COPD. While the latest GOLD statement places emphasis on a more broad assessment of the disease [2], there is still a need to refine the GOLD classification, to avoid misclassification of patients with mild COPD. Accordingly, phenotypes could be one promising approach to the clinical heterogeneity of COPD [6]; potentially helping to identify a better type of approach to use for patients with mild disease.

We took advantage of a cohort of symptomatic and asymptomatic patients with mild COPD to explore possible heterogeneity in GOLD 1 COPD and to evaluate whether different subtypes of patients could be identified within this GOLD category. We used cluster analysis to divide our population into subgroups (clusters) according to the clinical parameters included in the study. The participants were characterized in five different domains: 1) baseline characteristics; 2) symptoms; 3) baseline lung function; 4) peak exercise response; and 5) levels of physical activity (steps/day, daily energy expenditure >3 metabolic equivalents [METs], daily time >3 METs). Since the clinical significance of this relatively new category of patients with mild COPD has been questioned [7–9], we also included healthy control subjects in the cluster analysis to investigate how the GOLD 1 patients would be differentiated. Based on the notion that considerable heterogeneity exists within GOLD 2 to 4 COPD [10], we hypothesized that a similar phenomenon would be seen within the GOLD 1 category and that different clinical phenotypes could be identified.

Methods

Study Design and Subjects

Data for this study were obtained, pre-randomization, from a single-center study, aimed at characterizing mild COPD and its exercise response to bronchodilation (ClinicalTrials.gov identifier: NCT01360788) and a multicenter clinical study involving 14 investigation sites, aimed at evaluating exercise response to bronchodilation in mild-to-moderate COPD (NCT01072396). The protocols for the individual trials are available in [S1 Protocol](#)

the authors' adherence to PLOS ONE policies on sharing data and materials.

(NCT01360788) and [S2 Protocol](#) (NCT01072396). The patient characterization phase of NCT01072396 has been published by O'Donnell et al [11].

A total of 85 patients meeting the GOLD 1 COPD spirometric classification criteria (post-bronchodilator $FEV_1 \geq 80\%$ predicted and $FEV_1/FVC < 0.70$) [2] and a smoking history ≥ 10 pack-years were included in the study; 118 healthy subjects with normal spirometry ($FEV_1 > 80\%$ predicted and $FEV_1/FVC \geq 0.7$) served as controls. All subjects must have been in a stable condition for at least 6 weeks before study enrolment. Patients with COPD treated with short or long-acting β -adrenergic bronchodilators were asked to withdraw from their medication from 8 and 36 hours prior to the visit, respectively; similarly, short or long-acting anticholinergic bronchodilators were discontinued 8 hours and 2 weeks prior to the visit, respectively. This was done in order to avoid any confounding effects on exercise testing or pulmonary function. In all groups, subjects were excluded if they presented with any medical condition, other than COPD, likely to influence exercise testing as well as participation in physical activities of daily life (i.e. cardiovascular, neurological, musculoskeletal, locomotor or other respiratory diseases as well as β -blocker therapy).

Symptoms

The baseline dyspnea index (BDI) [12] was used to quantify the degree of dyspnea on a scale of 0 to 12, where a lower score denotes worse severity. Cough was considered present when occurring daily for 3 months per year, during at least 2 consecutive years.

Pulmonary Function Testing

Standard pulmonary function tests, including spirometry, lung volumes (by plethysmography) and diffusion capacity (D_{LCO}) were obtained according to previously described guidelines [13] and related to predicted normal values [14]. The FEV_1/FVC ratio was compared with the lower limit of the normal (LLN) range according to the National Health and Nutrition Examination Survey (NHANES) III predicted values [15]. The predicted value for inspiratory capacity (IC) was obtained by subtracting the functional residual capacity (FRC) predicted value from the total lung capacity (TLC) predicted value. Maximum voluntary ventilation (MVV) was estimated by multiplying FEV_1 by 35 [16].

Exercise Testing

Peak exercise capacity was determined using a walking exercise test, either an incremental shuttle walk test (ISWT) (NCT01360788) or an incremental treadmill exercise test (NCT01072396).

Incremental shuttle walking test. The originally described test [17], was modified to add three additional speed steps in order to reach symptom limitation in all participants [18]. Subjects were allowed to run in order to attain maximal exercise capacity. During the ISWT, subjects breathed through a facemask, connected to a portable gas exchange analyzer (Oxycon Mobile, Viasys Healthcare, Jaeger, Germany), which measured oxygen consumption ($V'O_2$), carbon dioxide output ($V'CO_2$) and minute ventilation ($V'E$). Dyspnea and leg fatigue Borg scores [19] were obtained at baseline and at end of exercise; with higher scores indicating worse severity. Finally, the locus of symptom limitation was determined by asking whether participants stopped exercise because of dyspnea/leg fatigue/both or for another reason.

Incremental treadmill exercise test. The incremental treadmill test was performed in a ramp-fashion adapted from the protocol established by Porszasz et al. [20], with a $10 \text{ W} \cdot \text{min}^{-1}$ and a $15 \text{ W} \cdot \text{min}^{-1}$ increase for patients with GOLD 1 COPD and control subjects, respectively. As for the ISWT, subjects were connected to a gas exchange analyzer using a mouthpiece and a

nose clip. Finally, the same procedure as for the ISWT was implemented for effort perception and locus of symptom limitation.

Levels of Physical Activity

Physical activity in daily life was monitored during 7 to 14 consecutive days via a monitor (SenseWear ArmBand, BodyMedia Inc., Pittsburgh, PA, USA), which was worn on the right upper arm for at least 12 hours per day. This device produced estimates of the steps taken per day, as well as daily time and energy expenditure associated with at least moderate intensity (>3 METs). We report the mean daily values over the period of measure.

Cluster Analysis

Hierarchical cluster analysis was used to define homogeneous groups of individuals based on given parameters [21]. This analysis was performed using Ward's minimum-variance method and distances between individuals were measured in the metric of the pooled within-cluster covariance matrix as proposed by Art and colleagues [22]. The analysis results in groups (clusters) of members who share strong associations, while these associations are weak between members of different clusters [23]. Hierarchical clustering methods first assigned each individual to their own cluster. Then the most similar pairs of clusters (in terms of the chosen distance metric) were merged into a new cluster, so that there was one less cluster. The iteration process continued by merging the next two similar clusters, or new clusters, until all individuals could be included in a cluster. The parameters included in the analysis are shown in Table 1. The number of clusters was determined by using three statistics (pseudo F statistic, pseudo t^2 statistic and cubic clustering criterion), which performed best in the simulation study of Milligan and Cooper [24].

Ethics Statement

The parent clinical trials, from which data were obtained for this cluster analysis study, were carried out in compliance with the approved protocols, the principles laid down in the

Table 1. Clinical parameters included in the analysis.

Domain	Parameters
Baseline characteristics	Age, sex, weight, height, BMI, smoking status (never/former/active), smoking history (pack-years)
Symptoms	Cough with sputum production for 3 months/year during ≥ 2 consecutive years (yes/no)
	BDI score (scale 0–12)
Lung function	% predicted value: FEV ₁ , FVC, IC, TLC, FRC, RV, D _{Lco}
	Ratio: FEV ₁ /FVC, IC/TLC, RV/TLC
	Lower limit of normal status: FEV ₁ /FVC (over/under)
Peak exercise response	V _{O₂ peak} (mL•kg ⁻¹ •min ⁻¹), V _{E peak} (L•min ⁻¹), V _{E peak} /MVV, V _T (% predicted VC), Bf, V _E /V _{O₂} , V _E /V _{CO₂} , dyspnea _{peak} (Borg score; scale 0–10), leg fatigue _{peak} (Borg score; scale 0–10), limiting factor (dyspnea/leg fatigue/both/other)
Levels of physical activity	Steps per day, daily energy expenditure >3 METs (kcal), daily time >3 METs (min)

BMI: body mass index; BDI: Baseline Dyspnea Index; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; IC: inspiratory capacity; TLC: total lung capacity; FRC: functional residual capacity; RV: residual volume; D_{Lco}: diffusion capacity; V_{O₂}: oxygen uptake; V_E: minute ventilation; MVV: maximal voluntary ventilation by multiplying FEV₁ by 35; V_T: tidal volume; VC: vital capacity; Bf: breathing frequency; V_{CO₂}: carbon dioxide output; METs: metabolic equivalents.

doi:10.1371/journal.pone.0123626.t001

Declaration of Helsinki version as of October 1996 and in accordance with the International Conference on Harmonisation Tripartite Guidelines for Good Clinical Practice. Written informed consent was obtained from all participants; the study protocols, informed consent and patient information were reviewed and approved by local Institutional Review Boards/Independent Ethics Committees. NCT01360788: Comité d'Éthique de la Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (Québec, QC). NCT01072396: Chesapeake Research Review, Inc. (Columbia, MD); The John F. Wolf, M.D. Human Subjects Committee of the Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center (Torrance, CA); Partners Human Research Committee (Boston, MA); Western Institutional Review Board (Olympia, WA); Springfield Committee for Research Involving Human Subjects (Springfield, IL); Trustees of Dartmouth College, Dartmouth-Hitchcock Medical Center, Committee for the Protection of Human Subjects (Hanover, NH); Saint Francis Hospital and Medical Center Institutional Review Board (Hartford, CT); McGill University Health Center Research Ethics Office (Montreal, QC); Comité d'Éthique de la Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (Québec, QC); Queen's University, Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (Kingston, ON); and Centre Hospitalier de l'Université de Montréal (CHUM) Research Ethics Committee (Montreal, QC).

Statistical Analysis

Results obtained in all patients with GOLD 1 COPD and controls were first shown as frequency distributions and compared between the two groups using Pearson's Chi-squared statistic tests. Second, comparisons were made between the clusters, which were identified through the cluster analysis. Quantitative variables, expressed as mean \pm standard deviation (SD), were compared among clusters using an analysis of variance (ANOVA) model. Following a significant finding, Tukey's post hoc multiple comparisons technique was used to compare each cluster with the other clusters. Qualitative variables, expressed as percentages, were compared among clusters using Pearson's chi-squared statistic test. All analyses were done at the level of significance of $p < 0.05$.

Results

Heterogeneity in GOLD 1 COPD

The frequency distributions for pulmonary function, peak $\dot{V}'O_2$, BDI score and physical activity are provided in [Fig 1](#). FEV₁% predicted, FEV₁/FVC and DLCO % predicted were lower while TLC, FRC and reserve volume (RV) were higher in patients with GOLD 1 COPD compared with controls (all $p < 0.001$). For all these variables, with the exception of FEV₁/FVC ratio, a considerable degree of overlap between GOLD 1 COPD and controls was seen. Compared with controls, peak $\dot{V}'O_2$ was lower on average by 15% in patients with COPD, who also expressed a lower BDI score. The number of steps per day tended to be reduced in COPD compared with control ($p = 0.09$). No difference was observed for daily time spent at physical activity > 3 METs between the two groups ($p = 0.47$).

Cluster Analysis

We obtained a three-cluster solution, which best fitted the parameters and subjects included in the study; this decision was based on local peaks of the cubic clustering criterion and pseudo F statistic combined with a small value of the pseudo t^2 statistic and a larger value for the next cluster fusion ([Fig 2a](#)) [24]. This was also in accordance with the dendrogram issued from the hierarchical Ward's clustering method ([Fig 2b](#)) [25]. Cluster I included 105 controls and 18




Fig 1. Frequency distributions for pulmonary function, peak V'O₂, BDI score and physical activity. a) forced expiratory volume in 1 second (FEV₁); b) FEV₁/forced vital capacity (FVC) ratio; c) total lung capacity (TLC); d) functional residual capacity (FRC); e) residual volume (RV); f) diffusion capacity (D_{LCO}); g) peak oxygen uptake (V'O_{2 peak}); h) baseline dyspnea index (BDI) score; i) number of steps per day; j) and daily time spent in physical activity >3 metabolic equivalents (METs). GOLD: Global Initiative for Chronic Obstructive Lung Disease.

doi:10.1371/journal.pone.0123626.g001




Fig 2. Determination of the number of clusters. a) Using three statistics (the statistical value of pseudo F statistic and cubic clustering criterion are reported on the left Y axis while the statistical value for pseudo t^2 statistic is reported on the right Y axis) and b) hierarchical Ward's clustering method.

doi:10.1371/journal.pone.0123626.g002

patients with GOLD 1 COPD, while clusters II and III were mostly composed of patients with GOLD 1 COPD (Fig 3).

The characteristics of the patients with COPD in the three clusters, excluding the controls from this analysis, are presented in Table 2. Patients in the three clusters had a similar body




Fig 3. Proportion of controls subjects and patients with GOLD grade 1 COPD within each cluster.

doi:10.1371/journal.pone.0123626.g003

mass index and sex distribution; patients in cluster III were older than those in cluster II ($p = 0.03$). Smoking history was significantly higher in patients belonging to cluster II than cluster I ($p = 0.002$). Prevalence of cough and dyspnea BDI scores was similar across the clusters (Table 2). Pulmonary function data are provided in Table 2 and Fig 4. Except for lung volumes in patients belonging to cluster I, other pulmonary function indices were impaired in patients in the three clusters compared with control values ($p < 0.01$; Fig 4). The three clusters of patients with COPD had similar FEV₁ (Fig 4), but FRC and RV were significantly increased in cluster II compared with cluster I ($p = 0.01$ and $p = 0.04$, respectively). Cluster II also tended to display a lower IC/TLC ratio compared with cluster I (0.43 ± 0.08 versus 0.48 ± 0.07 ; $p = 0.07$). Finally, cluster III was differentiated from clusters I and II by a significantly lower FEV₁/FVC ratio ($p = 0.002$ and $p = 0.008$, respectively).

Although patients in the three clusters had similar peak V'_{O₂}, only patients in clusters II and III showed a significantly reduced peak V'_{O₂} compared with controls ($p < 0.01$; Fig 5). The number of step per day and amounts of physical activity with energy expenditure > 3 METs was significantly reduced in patients in cluster III compared with controls ($p < 0.01$) and patients in clusters I ($p < 0.001$) and II ($p < 0.001$). As indicated in Table 3, patients belonging to cluster III differed from those of cluster II on the basis of a significantly higher V'_E/MVV ratio at peak exercise ($p < 0.001$). When compared with patients in clusters I and II, patients in Cluster III had significantly higher V'_E/V'_{O₂} ratio ($p = 0.005$ and $p = 0.05$, respectively), higher respiratory exchange ratio at peak exercise ($p = 0.01$ and $p < 0.001$, respectively) and were mainly limited by dyspnea ($p = 0.02$; Table 3).

Discussion

This study highlights heterogeneity in the clinical manifestations of GOLD 1 COPD, as defined by the 2014 GOLD consensus report [1]. Three clusters of patients with GOLD 1 COPD could be identified: cluster I was characterized by reduced DLCO and decreased BDI dyspnea scores (compared with controls) with preserved lung volumes, exercise capacity and physical activity levels; cluster II showed more prominent static hyperinflation (FRC) and gas trapping (RV) but preserved levels of physical activity; and cluster III exhibited marked reduction in physical activity levels and higher V'_E/MVV ratio, V'_E/V'_{O₂} and respiratory exchange ratio at peak exercise.

Heterogeneity in the clinical manifestations of COPD has been highlighted in patients involved in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) cohort [10]. The present study extends these results by showing a similar

Table 2. Characteristics of patients with GOLD grade 1 COPD by cluster.

Domain/Parameters	Cluster I (n = 18)	Cluster II (n = 45)	Cluster III (n = 22)	p-value		
				Cluster I versus II	Cluster I versus III	Cluster II versus III
Demographics						
Age, years	64 ± 6 [61–66]	61 ± 8 [58–64]	66 ± 6 [63–69]	0.46	0.58	0.03
Male, n (%)	9 (50)	30 (67)	14 (64)	0.46		
BMI, kg•m ⁻²	27 ± 3 [25–28]	27 ± 4 [26–28]	27 ± 4 [25–28]	0.68	0.96	0.84
Smoking status, former/active %	94/6	60/40	59/41	0.02		
Smoking history, pack-years	33 ± 15 [25–40]	51 ± 22 [45–58]	43 ± 15 [36–49]	0.002	0.21	0.20
Symptoms						
Cough, no/yes %	61/39	42/58	45/55	0.39		
BDI scale	8.5 ± 1.9 [7.6–9.4]	7.5 ± 2.1 [6.9–8.1]	8.3 ± 1.0 [7.8–8.7]	0.14	0.92	0.25
Lung function						
FEV ₁ , L	2.60 ± 0.67 [2.26–2.93]	2.79 ± 0.69 [2.58–3.00]	2.54 ± 0.62 [2.26–2.81]	0.55	0.96	0.31
FEV ₁ , % predicted	94 ± 12 [88–100]	97 ± 13 [94–101]	95 ± 10 [91–100]	0.63	0.95	0.82
FVC, L	4.00 ± 0.98 [3.51–4.49]	4.44 ± 1.14 [4.10–4.78]	4.30 ± 0.99 [3.86–4.75]	0.30	0.63	0.88
FVC, % predicted	118 ± 13 [111–124]	124 ± 14 [119–128]	130 ± 17 [122–137]	0.32	0.02	0.22
FEV ₁ /FVC, %	65 ± 5 [63–67]	63 ± 5 [62–65]	59 ± 6 [56–62]	0.54	0.002	0.008
FEV ₁ /FVC, <LLN %	61	76	86	0.18		
IC, L	3.09 ± 0.91 [2.64–3.55]	3.03 ± 1.02 [2.72–3.34]	2.99 ± 0.80 [2.64–3.35]	0.96	0.94	0.99
IC, % predicted	110 ± 20 [100–120]	104 ± 21 [98–110]	109 ± 19 [100–118]	0.57	0.99	0.63
TLC, L	6.33 ± 1.16 [5.75–6.90]	6.95 ± 1.62 [6.46–7.44]	6.60 ± 1.22 [6.06–7.14]	0.27	0.82	0.62
TLC, % predicted	107 ± 12 [101–113]	113 ± 15 [109–118]	111 ± 11 [106–116]	0.20	0.52	0.86
FRC, L	3.25 ± 0.45 [3.03–3.48]	3.92 ± 0.95 [3.64–4.22]	3.64 ± 0.83 [3.28–4.02]	0.01	0.32	0.40
FRC, % predicted	104 ± 16 [96–112]	122 ± 25 [114–129]	114 ± 23 [104–125]	0.02	0.37	0.45
RV, L	2.24 ± 0.41 [2.05–2.45]	2.71 ± 0.81 [2.47–2.95]	2.48 ± 0.50 [2.26–2.70]	0.04	0.53	0.38
RV, % predicted	102 ± 17 [93–110]	123 ± 36 [112–134]	110 ± 23 [100–120]	0.03	0.68	0.21
IC/TLC	0.48 ± 0.07 [0.45–0.52]	0.43 ± 0.08 [0.41–0.46]	0.45 ± 0.09 [0.41–0.49]	0.07	0.52	0.58
RV/TLC	0.36 ± 0.05 [0.33–0.39]	0.39 ± 0.08 [0.37–0.42]	0.38 ± 0.07 [0.35–0.42]	0.27	0.64	0.84
D _{Lo} , % predicted	79 ± 15 [72–87]	76 ± 23 [69–83]	73 ± 18 [65–82]	0.86	0.64	0.85
Comorbidities						
Hypertension, n (%)	8 (44)	16 (36)	6 (27)	–	–	–
Dyslipidemia, n (%)	7 (39)	16 (36)	7 (32)	–	–	–
Coronary heart disease, n (%)	1 (6)	5 (11)	0 (0)	–	–	–
Diabetes, n (%)	0 (0)	2 (4)	0 (0)	–	–	–
Neoplasia, n (%)	2 (11)	0 (0)	0 (0)	–	–	–

Data are mean ± SD [95% confidence interval], unless otherwise specified.

Reported p-values for the ordinal variables (distribution) refer to Chi-squared test values from the contingency analysis.

BMI: body mass index; BDI: baseline dyspnea index; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; LLN: lower limit of normal; IC: inspiratory capacity; TLC: total lung capacity; FRC: functional residual capacity; RV: residual volume; D_{Lo}: diffusion capacity.

doi:10.1371/journal.pone.0123626.t002




Fig 4. Pulmonary function parameters expressed as percentage of predicted values by cluster. a) forced expiratory volume in 1 second (FEV₁); b) total lung capacity (TLC); c) functional residual volume (FRC); d) residual volume (RV); and e) diffusion capacity (DL_{CO}); as well as f) FEV₁/forced vital capacity (FVC) ratio by cluster of patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 1 chronic obstructive pulmonary disease. Values are mean ± SD. Dashed lines represent mean values in control subjects. *p<0.01 versus healthy controls; †p<0.05 versus cluster I; ‡p<0.01 versus cluster I and II.

doi:10.1371/journal.pone.0123626.g004




Fig 5. $V'O_{2\text{ peak}}$ relative to body weight and daily physical activity levels by cluster. a) Peak oxygen consumption ($V'O_{2\text{ peak}}$) relative to body weight; b) mean steps per day; c) mean daily energy expenditure (EE); d) mean daily time >3 metabolic equivalents (METs); and e) baseline dyspnea index (BDI) score by cluster of patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade 1 chronic obstructive pulmonary disease. Values are mean \pm SD. Dashed lines represent mean values in control subjects. * $p<0.01$ versus controls subjects; † $p<0.05$ versus cluster I and II.

doi:10.1371/journal.pone.0123626.g005

phenomenon within the GOLD 1 COPD category. One potential implication of these findings is that all patients within the GOLD 1 COPD category should not be considered as having the same disease. Some of them (cluster I) may exhibit preserved functional capacity and physical activity levels despite evidence of airflow obstruction. It could be argued that patients belonging

Table 3. Peak physiological response to exercise for patients with GOLD grade COPD by cluster.

Parameter	Cluster I (n = 18)	Cluster II (n = 45)	Cluster III (n = 22)	p-value		
				Cluster I versus II	Cluster I versus III	Cluster II versus III
$\dot{V}O_{2\text{ peak}}$, mL•kg ⁻¹ •min ⁻¹	26.3 ± 6.1 [23.2–29.3]	23.7 ± 5.5 [22.1–25.4]	24.5 ± 4.6 [22.4–26.5]	0.22	0.56	0.85
$\dot{V}E$, L•min ⁻¹	73 ± 25 [61–86]	72 ± 25 [64–80]	77 ± 19 [68–85]	0.98	0.89	0.73
$\dot{V}E/MVV$	80 ± 17 [72–89]	73 ± 15 [68–78]	87 ± 7 [83–90]	0.15	0.33	<0.001
V_T , % predicted VC	56 ± 11 [51–62]	54 ± 9 [52–57]	61 ± 9 [58–65]	0.71	0.23	0.01
Bf , breaths•min ⁻¹	39 ± 8 [35–43]	37 ± 7 [35–40]	40 ± 7 [38–44]	0.74	0.71	0.19
$\dot{V}E/\dot{V}O_2$	36 ± 5 [34–38]	38 ± 7 [36–40]	42 ± 5 [40–44]	0.34	0.005	0.05
$\dot{V}E/\dot{V}CO_2$	33 ± 4 [31–35]	35 ± 6 [34–37]	34 ± 5 [32–37]	0.16	0.58	0.72
RER	1.11 ± 0.13 [1.04–1.17]	1.09 ± 0.16 [1.04–1.14]	1.23 ± 0.11 [1.18–1.28]	0.88	0.01	<0.001
Dyspnea _{peak} Borg score	5.7 ± 1.4 [5.1–6.5]	6.4 ± 2.5 [5.6–7.1]	6.8 ± 1.5 [6.1–7.4]	0.57	0.30	0.75
Leg fatigue _{peak} Borg score	4.8 ± 2.4 [3.6–5.9]	5.6 ± 2.7 [4.8–6.5]	5.3 ± 2.3 [4.3–6.3]	0.44	0.79	0.86
Limiting factor dyspnea/legs/both/other, %	28/55/17/0	24/38/38/0	59/23/18/0	0.02		

Data are mean ± SD [95% confidence interval], unless otherwise specified.

Reported p-values for the ordinal variables (distribution) refer to Chi-Squared test values from the contingency analysis.

$\dot{V}O_2$: oxygen uptake; $\dot{V}E$: minute ventilation; MVV: maximal voluntary ventilation by multiplying FEV₁ by 35; V_T : tidal volume; VC: vital capacity; Bf : breathing frequency; $\dot{V}CO_2$: carbon dioxide output; RER: respiratory exchange ratio.

doi:10.1371/journal.pone.0123626.t003

to cluster I were actually healthy subjects who were misclassified based on a fixed FEV₁/FVC ratio [26]. This issue of misclassification is supported by the fact that the FEV₁/FVC ratio was >LLN in 39% of subjects. Conversely, decreased BDI dyspnea scores and reduced DLCO found in this cluster would argue that these patients were nevertheless showing some pathophysiological features of COPD. Clearly, the delineation between healthy smokers and mild COPD is not necessarily perfect, illustrating that the differentiation between health and disease is likely to be a continuum. However, by combining both healthy controls and patients with GOLD 1 COPD in a cluster analysis we have illustrated that the majority of GOLD 1 patients (67/85, 79%) stood out as being different from most healthy controls, which supports the notion that these individuals exhibit clinical features of a “true” disease.

Patients with GOLD 1 COPD included in cluster II were mostly characterized by a substantial smoking history (>50 pack-years) and, from a physiological standpoint, by FRC and RV >120% predicted and reduced exercise capacity. Surprisingly, the levels of physical activity were still preserved in cluster II. It is also interesting to consider that vital capacity was preserved in these individuals despite static hyperinflation and gas trapping. This finding in patients with mild airflow obstruction has been previously reported in cross-sectional studies and may have important implications in terms of maintaining ventilatory capacity during exercise [27–30].

Patients with mild COPD in cluster III were mainly characterized by a lower FEV₁/FVC ratio, reduced exercise capacity and striking reduction in the level of physical activity compared with the other clusters. Reduced physical activity level has already been reported in patients with GOLD 1 COPD [31,32]. Our data add to the existing literature by showing that this reduction in physical activity may be occurring only in a subset of patients with GOLD 1 COPD. Considering the strong negative prognostic implications of low physical activity levels in COPD [33,34], our analysis may have identified a category of mild COPD that is at higher risk of poor outcomes. Taking into account that increasing physical activity represents an

important objective of pulmonary rehabilitation [35], our results support a possible role of this intervention in mild COPD, particularly when FEV_1/FVC is low. Interestingly, this profound reduction in physical activity level seen in cluster III in comparison with the other two clusters of patients with COPD was present despite similar peak $V'O_2$. This dissociation between peak exercise capacity and level of physical activity is important because it illustrates that these two parameters are assessing different concepts and that although preserved peak exercise capacity is permissive to physical activity, it does not guarantee an active lifestyle [36]. We do not have a clear explanation for the reduced level of physical activity in cluster III. These patients had a higher erosion of the ventilatory reserve at peak exercise [37] in comparison with the other clusters and they were mostly limited by dyspnea at peak exercise. In the face of a similar $V'E/V'O_2$, the higher $V'E/V'O_2$ and respiratory exchange ratio observed at peak exercise in these patients may reflect greater metabolic acidosis, perhaps due to higher reliance of the limb muscles on glycolytic metabolism. Although we can only speculate on this issue, it is interesting to consider that evidence of limb muscle dysfunction has been reported in patients with mild COPD [38,39]. Being more physically inactive, this subset of patients may be at a greater risk of developing limb muscle dysfunction.

In this study, we used the GOLD classification [1] to stratify our patients because of its wide clinical application. However, we appreciate the fact that any attempt to categorize disease severity based on FEV_1 cut-offs is arbitrary in nature and that, in fact, COPD severity is a continuum. Stratifying patients into subcategories is particularly useful when it helps in disease prognostication or in individualizing clinical management. We acknowledge that we have not reached this goal with the current study. The main purpose of the present cluster analysis was to highlight heterogeneity in GOLD 1 COPD patients; an information potentially useful for future studies in this specific patient population. Our results emphasize that the clinical manifestations of COPD are heterogeneous, even within the same GOLD severity category, and that the evaluation of a patient should not rely solely on FEV_1 . We appreciate that respiratory symptoms were measured only once and that they may fluctuate over time [40]. In order to avoid potential misclassifications for respiratory symptoms, all participants were studied in a stable condition. Given the majority of men in our study, caution should be taken before applying the findings to women with mild COPD. One further potential limitation was that exacerbations were not systematically recorded in this population. Patients involved in study NCT01360788 did not report any exacerbation in the year preceding their involvement in the study, whereas patients involved in study NCT01072396 had to be stable for 6 weeks before the trial. Therefore, we are confident that exacerbation was not a major issue in this population and that this information would not have had a substantial impact on the outcomes of the cluster analysis. It is acknowledged that the sample size for this study is relatively small, since larger sample sizes are not available. However, this is the first time that such a group of patients with GOLD 1 COPD has been thoroughly investigated, and the results should be followed up with a larger sample size when available.

Patient data used in this study were pooled from two clinical trials. Some patients were initially identified through a lung cancer screening study, during which spirometry was performed, and when they had completed their participation in the study, they were referred on for participation in NCT01360788. Patients in NCT01072396 were recruited through respiratory clinics in order to evaluate the exercise response to bronchodilation in mild-to-moderate COPD. The resultant patient population for our cluster analysis included a mixture of asymptomatic and symptomatic patients; this is reflected in the heterogeneity that was found in this population. How truly representative this cohort is of the entire GOLD 1 COPD population is difficult to assess but we nevertheless believe that we covered a spectrum of the GOLD 1 COPD population.

Conclusions

In conclusion, our study highlights heterogeneity within the GOLD grade 1 COPD category. Three clusters of patients with mild COPD were identified: 1) patients with reduced FEV₁/FVC ratio and DLCO who otherwise behave like healthy subjects; 2) patients with signs of static hyperinflation but preserved levels of physical activity; and 3) patients with profound reduction in the level of physical activity also exhibiting further reduced ventilatory reserve at peak exercise as well as higher dyspnea score and evidence of more profound metabolic acidosis compared with the other clusters. These results support a more individualized therapeutic approach to patients with GOLD 1 COPD, with some patients potentially only requiring smoking cessation while others being potential candidates for more intense interventions, such as bronchodilation, exercise training and physical activity promotion interventions. This hypothesis and the robustness of our findings will need confirmation in additional population samples.

Supporting Information

S1 Dataset.

(XLS)

S1 Protocol. NCT01360788 clinical trial protocol.

(PDF)

S2 Protocol. NCT01072396 clinical trial protocol.

(PDF)

Acknowledgments

The authors acknowledge the help of Marthe Bélanger, Marie-Josée Breton, Brigitte Jean and Josée Picard in accomplishing this study, are grateful to Eric Nadreau for his technical support during the exercise testing and thank Carole St-Pierre for her help in the recruitment (all at the Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada). The authors also thank Gaétan Daigle for statistical assistance (Service de Consultation Statistique, Université Laval, Québec).

Author Contributions

Conceived and designed the experiments: PG RC DS JP DEO FM. Performed the experiments: PG RC DS JP SP JM JB DEO FM. Analyzed the data: PG RC DS FM. Contributed reagents/materials/analysis tools: PG RC DEO FM. Wrote the paper: PG RC DS JP SP JM JB DEO FM.

References

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. January 2014. Available: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdf. Accessed 29 April 2014.
2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2013; 187: 347–365. doi: [10.1164/rccm.201204-0596PP](https://doi.org/10.1164/rccm.201204-0596PP) PMID: [22878278](https://pubmed.ncbi.nlm.nih.gov/22878278/)
3. Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. *Eur Respir J*. 2010; 36: 531–539. doi: [10.1183/09031936.00175109](https://doi.org/10.1183/09031936.00175109) PMID: [20075045](https://pubmed.ncbi.nlm.nih.gov/20075045/)

4. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. *Lancet*. 2007; 370: 741–750. PMID: [17765523](#)
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. November 2006. Available: http://www.goldcopd.org/uploads/users/files/GOLDReport2006_0122.pdf. Accessed 29 April 2014.
6. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. *Am J Respir Crit Care Med*. 2010; 182: 598–604. doi: [10.1164/rccm.200912-1843CC](#) PMID: [20522794](#)
7. Mannino DM, Buist AS, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? *Thorax*. 2007; 62: 237–241. PMID: [17090573](#)
8. Kerstjens HA. The GOLD classification has not advanced understanding of COPD. *Am J Respir Crit Care Med*. 2004; 170: 212–213. PMID: [15280172](#)
9. Petsonk EL, Hnizdo E, Attfield M. Definition of COPD GOLD stage I. *Thorax*. 2007; 62: 1107–1108. PMID: [18025146](#)
10. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. *Respir Res*. 2010; 11: 122. doi: [10.1186/1465-9921-11-122](#) PMID: [20831787](#)
11. O'Donnell DE, Maltais F, Porszasz J, Webb KA, Albers FC, Deng Q, et al. The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. *PLoS ONE*. 2014; 9: e96574. doi: [10.1371/journal.pone.0096574](#) PMID: [24788342](#)
12. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. *Chest*. 1984; 85: 751–758. PMID: [6723384](#)
13. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005; 26: 948–968. PMID: [16264058](#)
14. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl*. 1993; 16: 5–40. PMID: [8499054](#)
15. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med*. 1999; 159: 179–187. PMID: [9872837](#)
16. Gandevia B, Hugh-Jones P. Terminology for measurements of ventilatory capacity; a report to the thoracic society. *Thorax*. 1957; 12: 290–293. PMID: [13496030](#)
17. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax*. 1992; 47: 1019–1024. PMID: [1494764](#)
18. Gagnon P, Saey D, Provencher S, Milot J, Bourbeau J, Tan WC, et al. Walking exercise response to bronchodilation in mild COPD: a randomized trial. *Respir Med*. 2012; 106: 1695–1705. doi: [10.1016/j.rmed.2012.08.021](#) PMID: [22999808](#)
19. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc*. 1982; 14: 377–381. PMID: [7154893](#)
20. Porszasz J, Casaburi R, Somfay A, Woodhouse LJ, Whipp BJ. A treadmill ramp protocol using simultaneous changes in speed and grade. *Med Sci Sports Exerc*. 2003; 35: 1596–1603. PMID: [12972882](#)
21. McLachlan GJ. Cluster analysis and related techniques in medical research. *Stat Methods Med Res*. 1992; 1: 27–48. PMID: [1341650](#)
22. Art D, Gnanadesikan R, Kettenring R (1982) Data-based metrics for cluster analysis. *Utilitas Mathematica*. pp. 75–99.
23. Weatherall M, Shirtcliffe P, Travers J, Beasley R. Use of cluster analysis to define COPD phenotypes. *Eur Respir J*. 2010; 36: 472–474. doi: [10.1183/09031936.00035210](#) PMID: [20930198](#)
24. Milligan GW, Cooper MC. An examination of procedures for determining the number of clusters in a data set. *Psychometrika*. 1985; 50: 159–179.
25. Ward JH. Hierarchical grouping to optimize an objective function. *J Am Stat Assoc*. 1963; 58: 236–244.
26. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV₁/FVC ratio reduces the misclassification of airway obstruction. *Thorax*. 2008; 63: 1046–1051. doi: [10.1136/thx.2008.098483](#) PMID: [18786983](#)

27. Deesomchok A, Webb KA, Forkert L, Lam YM, Ofir D, Jensen D, et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. *COPD*. 2010; 7: 428–437. doi: [10.3109/15412555.2010.528087](https://doi.org/10.3109/15412555.2010.528087) PMID: [21166631](https://pubmed.ncbi.nlm.nih.gov/21166631/)
28. Guenette JA, Jensen D, Webb KA, Ofir D, Raghavan N, O'Donnell DE. Sex differences in exertional dyspnea in patients with mild COPD: physiological mechanisms. *Respiratory physiology & neurobiology*. 2011; 177: 218–227.
29. Macklem PT. Therapeutic implications of the pathophysiology of COPD. *Eur Respir J*. 2010; 35: 676–680. doi: [10.1183/09031936.00120609](https://doi.org/10.1183/09031936.00120609) PMID: [20190332](https://pubmed.ncbi.nlm.nih.gov/20190332/)
30. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2008; 177: 622–629. PMID: [18006885](https://pubmed.ncbi.nlm.nih.gov/18006885/)
31. Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. *Respir Med*. 2010; 104: 1005–1011. doi: [10.1016/j.rmed.2010.01.012](https://doi.org/10.1016/j.rmed.2010.01.012) PMID: [20167463](https://pubmed.ncbi.nlm.nih.gov/20167463/)
32. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. *Eur Respir J*. 2009; 33: 262–272. doi: [10.1183/09031936.00024608](https://doi.org/10.1183/09031936.00024608) PMID: [19010994](https://pubmed.ncbi.nlm.nih.gov/19010994/)
33. Garcia-Rio F, Rojo B, Casitas R, Lores V, Madero R, Romero D, et al. Prognostic value of the objective measurement of daily physical activity in patients with COPD. *Chest*. 2012; 142: 338–346. PMID: [22281798](https://pubmed.ncbi.nlm.nih.gov/22281798/)
34. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. *Chest*. 2011; 140: 331–342. doi: [10.1378/chest.10-2521](https://doi.org/10.1378/chest.10-2521) PMID: [21273294](https://pubmed.ncbi.nlm.nih.gov/21273294/)
35. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An Official American Thoracic Society/European Respiratory Society Statement: Key concepts and advances in pulmonary rehabilitation—An Executive Summary. *Am J Respir Crit Care Med*. 2013; 188: e13–e64. doi: [10.1164/rccm.201309-1634ST](https://doi.org/10.1164/rccm.201309-1634ST) PMID: [24127811](https://pubmed.ncbi.nlm.nih.gov/24127811/)
36. Van Remoortel H, Hornikx M, Demeyer H, Langer D, Burtin C, Decramer M, et al. Daily physical activity in subjects with newly diagnosed COPD. *Thorax*. 2013; 68: 962–963. doi: [10.1136/thoraxjnl-2013-203534](https://doi.org/10.1136/thoraxjnl-2013-203534) PMID: [23604460](https://pubmed.ncbi.nlm.nih.gov/23604460/)
37. Sue DY, Hansen JE. Normal values in adults during exercise testing. *Clin Chest Med*. 1984; 5: 89–98. PMID: [6723246](https://pubmed.ncbi.nlm.nih.gov/6723246/)
38. Coronell C, Orozco-Levi M, Méndez R, Ramírez-Sarmiento A, Gáldiz JB, Gea J. Relevance of assessing quadriceps endurance in patients with COPD. *Eur Respir J*. 2004; 24: 129–136. PMID: [15293615](https://pubmed.ncbi.nlm.nih.gov/15293615/)
39. Seymour JM, Spruit MA, Hopkinson NS, Natanek SA, Man WD, Jackson A, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. *Eur Respir J*. 2010; 36: 81–88. doi: [10.1183/09031936.00104909](https://doi.org/10.1183/09031936.00104909) PMID: [19897554](https://pubmed.ncbi.nlm.nih.gov/19897554/)
40. Eagan TM, Gulsvik A, Eide GE, Bakke PS. Remission of respiratory symptoms by smoking and occupational exposure in a cohort study. *Eur Respir J*. 2004; 23: 589–594. PMID: [15083759](https://pubmed.ncbi.nlm.nih.gov/15083759/)